CEP
KERX

Chicago Equity Partners’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Chicago Equity Partners’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-198,730
Closed -$747K – 933
2018
Q2 		$747K Hold
198,730
– – 0.02% 579
2018
Q1 		$813K Sell
198,730
-144,305
-42% -$672K 0.03% 534
2017
Q4 		$1.59M Sell
343,035
-90,890
-21% -$501K 0.05% 411
2017
Q3 		$3.08M Buy
433,925
+52,720
+14% +$379K 0.1% 282
2017
Q2 		$2.76M Buy
+381,205
New +$2.38M 0.07% 310

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PIMJS
PKO Investment Management Joint-Stock Warsaw, Poland $1.38B AUM 59.54% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Chicago Equity Partners's KERX Position: Q3 2018 in Review

Chicago Equity Partners sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2018, closing a stake of 198,730 shares — an estimated $747K sold.

Chicago Equity Partners first reported a position in KERX in Q2 2017 and held it in 5 quarters. The position peaked at $3.08M in Q3 2017. 123 funds tracked by Wall St. Rank hold KERX as of Q3 2018.

  • Chicago Equity Partners reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2018 after selling out during the quarter.
  • Chicago Equity Partners sold 198,730 Keryx Biopharmaceuticals Inc shares in Q3 2018, an estimated $747K.
  • Chicago Equity Partners first reported a position in Keryx Biopharmaceuticals Inc in Q2 2017 and held it in 5 quarters.
  • Chicago Equity Partners's Keryx Biopharmaceuticals Inc position peaked at $3.08M in Q3 2017.
  • 123 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2018.

Based on Chicago Equity Partners's 13F filing for Q3 2018, filed 1 Nov 2018.